"Receptors, Histamine H3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of histamine receptors discriminated by their pharmacology and mode of action. Histamine H3 receptors were first recognized as inhibitory autoreceptors on histamine-containing nerve terminals and have since been shown to regulate the release of several neurotransmitters in the central and peripheral nervous systems. (From Biochem Soc Trans 1992 Feb;20(1):122-5)
| Descriptor ID |
D018100
|
| MeSH Number(s) |
D12.776.543.750.670.450.500 D12.776.543.750.720.480.500
|
| Concept/Terms |
Receptors, Histamine H3- Receptors, Histamine H3
- H3 Receptors
- Receptors, H3
- Histamine H3 Receptor
- H3 Receptor, Histamine
- Receptor, Histamine H3
- Histamine H3 Receptors
- H3 Receptors, Histamine
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Histamine H3".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Histamine H3".
This graph shows the total number of publications written about "Receptors, Histamine H3" by people in this website by year, and whether "Receptors, Histamine H3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Receptors, Histamine H3" by people in Profiles.
-
Gondard E, Anaclet C, Akaoka H, Guo RX, Zhang M, Buda C, Franco P, Kotani H, Lin JS. Enhanced histaminergic neurotransmission and sleep-wake alterations, a study in histamine H3-receptor knock-out mice. Neuropsychopharmacology. 2013 May; 38(6):1015-31.
-
Guo RX, Anaclet C, Roberts JC, Parmentier R, Zhang M, Guidon G, Buda C, Sastre JP, Feng JQ, Franco P, Brown SH, Upton N, Medhurst AD, Lin JS. Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice. Br J Pharmacol. 2009 May; 157(1):104-17.
-
Ligneau X, Landais L, Perrin D, Piriou J, Uguen M, Denis E, Robert P, Parmentier R, Anaclet C, Lin JS, Burban A, Arrang JM, Schwartz JC. Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol. 2007 Apr 15; 73(8):1215-24.
-
Parmentier R, Anaclet C, Guhennec C, Brousseau E, Bricout D, Giboulot T, Bozyczko-Coyne D, Spiegel K, Ohtsu H, Williams M, Lin JS. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol. 2007 Apr 15; 73(8):1157-71.
-
Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau A, Gbahou F, Arrang JM, Ganellin CR, Stark H, Schunack W, Schwartz JC. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. J Pharmacol Exp Ther. 2007 Jan; 320(1):365-75.